AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3994348 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 254
Study 3994348 — intervention group
Group type: COMPARATOR
Intervention: Moxalactam
Number of subjects: 254
Study 30711295 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading of dental implants with bar overdentures (n=35)
Number of subjects: 51
Study 30711295 — intervention group
Group type: COMPARATOR
Intervention: Conventional delayed loading protocol (n=16)
Number of subjects: 51
Study 28973782 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar anodal transcranial direct current stimulation (a‐tDCS), 20 min, 1.5 mA
Number of subjects: 29
Study 28973782 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 29
Study 25627581 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBond FL (three‐step etch‐and‐rinse)
Number of subjects: 45
Study 25627581 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBond SOLO Plus (two‐step etch‐and‐rinse)
Number of subjects: 45
Study 25627581 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBond XTR (two‐step self‐etch)
Number of subjects: 45
Study 25627581 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBond All‐in One (one‐step self‐etch)
Number of subjects: 45
Study 23525780 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Bodies, Healthy Souls (HBHS) intervention
Number of subjects: 0
Study 21499671 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory ergonomics (PE) program
Number of subjects: 3047
Study 21499671 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PE)
Number of subjects: 3047
Study 19155011 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE, 0.625 mg/day)
Number of subjects: 256
Study 19155011 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE (0.625 mg/day) plus medroxyprogesterone acetate (MPA, 2.5mg/day)
Number of subjects: 256
Study 19155011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study 17222641 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolapse reduction
Number of subjects: 31
Study 17222641 — intervention group
Group type: COMPARATOR
Intervention: Everted prolapse
Number of subjects: 31
Study 15075543 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg, eight doses administered subcutaneously twice weekly beginning on day 4 of tuberculosis therapy
Number of subjects: 16
Study 15075543 — intervention group
Group type: COMPARATOR
Intervention: Historical controls (not specified)
Number of subjects: 16
Study 11848191 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) only (Group 1, n = 8)
Number of subjects: 29
Study 11848191 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing before splinting (Group 2, n = 10)
Number of subjects: 29
Study 11848191 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing after splinting (Group 3, n = 11)
Number of subjects: 29
Study 10021962 — intervention group
Group type: EXPERIMENTAL
Intervention: 27-G Quincke needle
Number of subjects: 200
Study 10021962 — intervention group
Group type: EXPERIMENTAL
Intervention: 27-G Whitacre needle
Number of subjects: 200
Study 10021962 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (comparative group)
Number of subjects: 200
Study 10021962 — intervention group
Group type: EXPERIMENTAL
Intervention: Women (subgroup)
Number of subjects: 200
Study 10021962 — intervention group
Group type: EXPERIMENTAL
Intervention: Men (subgroup)
Number of subjects: 200
Study 7512334 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser photocoagulation
Number of subjects: 373
Study 7512334 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 373
Study 3228283 — intervention group
Group type: EXPERIMENTAL
Intervention: Active marijuana (2.3% delta 9 THC)
Number of subjects: 6
Study 3228283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31841136 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued bivalirudin infusion after PCI
Number of subjects: 13870
Study 31841136 — intervention group
Group type: COMPARATOR
Intervention: No bivalirudin infusion after PCI
Number of subjects: 13870
Study 31353231 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoprotein apheresis
Number of subjects: 20
Study 31353231 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 20
Study 27503938 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid for nutrition support
Number of subjects: 46
Study 26011261 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture pretreatment (EAP)
Number of subjects: 388
Study 23823815 — intervention group
Group type: EXPERIMENTAL
Intervention: IntraLase femtosecond laser
Number of subjects: 161
Study 23823815 — intervention group
Group type: EXPERIMENTAL
Intervention: Moria One Use‐Plus SBK
Number of subjects: 161
Study 23823815 — intervention group
Group type: COMPARATOR
Intervention: Moria M2 Single‐Use 90 µm‐head microkeratome
Number of subjects: 161
Study 21810165 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone 12 mg subcutaneous daily for 4 weeks
Number of subjects: 137
Study 19524353 — intervention group
Group type: EXPERIMENTAL
Intervention: Pollen extract (Cernilton)
Number of subjects: 139
Study 19524353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 16686911 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptan treatment
Number of subjects: 18
Study 16686911 — intervention group
Group type: COMPARATOR
Intervention: Untreated migraine attacks
Number of subjects: 18
Study 15560164 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Number of subjects: 289
Study 15560164 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemosorption and plasmapheresis in one contour
Number of subjects: 289
Study 15560164 — intervention group
Group type: EXPERIMENTAL
Intervention: Efferent therapy after medication and photomodification of the blood
Number of subjects: 289
Study 15560164 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted reproductive technologies
Number of subjects: 289
Study 12670352 — intervention group
Group type: COMPARATOR
Intervention: Desferrioxamine (DFX) alone (40‐50 mg/kg/d s.c. over 8‐12 h, five times weekly)
Number of subjects: 25
Study 12670352 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined DFX twice weekly and deferiprone (75 mg/kg/d)
Number of subjects: 25
Study 10955654 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabecular aspiration with phacoemulsification and IOL implantation
Number of subjects: 40
Study 10955654 — intervention group
Group type: COMPARATOR
Intervention: Standard filtering glaucoma triple procedure (phaco‐trab)
Number of subjects: 40
Study 10955654 — intervention group
Group type: COMPARATOR
Intervention: Phaco‐trab group
Number of subjects: 40
Study 10955654 — intervention group
Group type: EXPERIMENTAL
Intervention: Phaco‐aspiration group
Number of subjects: 40
Study 8888670 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary stenting
Number of subjects: 0
Study 8888670 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation management
Number of subjects: 0
Study 1443951 — intervention group
Group type: EXPERIMENTAL
Intervention: Education plus HIV testing
Number of subjects: 370
Study 1443951 — intervention group
Group type: EXPERIMENTAL
Intervention: Education alone
Number of subjects: 370
Study 1443951 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 370
Study 2859714 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 40
Study 2859714 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 40
Study 2859714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30657232 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized Timed Up and Go (TUG) Test
Number of subjects: 30
Study 29570164 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic machine perfusion (HMP)
Number of subjects: 752
Study 29570164 — intervention group
Group type: COMPARATOR
Intervention: Static cold storage (CS)
Number of subjects: 752
Study 29570164 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold ischemia time (CIT)
Number of subjects: 752
Study 26826069 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-pressure condition (mean response time = 96.00 seconds)
Number of subjects: 42
Study 26826069 — intervention group
Group type: COMPARATOR
Intervention: Control condition (mean response time = 151.97 seconds)
Number of subjects: 42
Study 24811615 — intervention group
Group type: COMPARATOR
Intervention: Diet
Number of subjects: 593
Study 24811615 — intervention group
Group type: COMPARATOR
Intervention: Diet plus physical activity
Number of subjects: 593
Study 22385038 — intervention group
Group type: EXPERIMENTAL
Intervention: MicroPlaSter alpha device (2 min cold atmospheric argon plasma treatment)
Number of subjects: 24
Study 22385038 — intervention group
Group type: EXPERIMENTAL
Intervention: MicroPlaSter beta device (2 min cold atmospheric argon plasma treatment)
Number of subjects: 24
Study 20332772 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (75 mg hora somni)
Number of subjects: 43
Study 20332772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 20332772 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 43
Study 18329226 — intervention group
Group type: EXPERIMENTAL
Intervention: Gay-specific cognitive-behavioral therapy (GCBT, n = 64)
Number of subjects: 128
Study 18329226 — intervention group
Group type: COMPARATOR
Intervention: Gay-specific social support therapy (GSST, n = 64)
Number of subjects: 128
Study 18329226 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (GCBT and GSST)
Number of subjects: 128
Study 16143248 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab (20 mg)
Number of subjects: 56
Study 16143248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 16143248 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 56
Study 12756512 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg daidzein twice daily for 10 days
Number of subjects: 20
Study 12756512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10051505 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) therapy
Number of subjects: 101
Study 10051505 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) therapy with steroid priming
Number of subjects: 101
Study 10051505 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 101
Study 8595083 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine (5 mg/kg body weight/day) for 4 weeks
Number of subjects: 20
Study 8595083 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine treatment
Number of subjects: 20
Study 8595083 — intervention group
Group type: COMPARATOR
Intervention: Normotensive subjects (control group)
Number of subjects: 20
Study 1709446 — intervention group
Group type: EXPERIMENTAL
Intervention: Single infusion of gamma globulin (2 g/kg over 10 hours)
Number of subjects: 549
Study 1709446 — intervention group
Group type: COMPARATOR
Intervention: Four daily infusions of gamma globulin (400 mg/kg for four consecutive days)
Number of subjects: 549
Study 1709446 — intervention group
Group type: COMPARATOR
Intervention: Both groups (single infusion and four daily infusions)
Number of subjects: 549
Study 7027425 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/d antrafenine
Number of subjects: 42
Study 7027425 — intervention group
Group type: COMPARATOR
Intervention: 3 g/d aspirin
Number of subjects: 42
Study 31210140 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial asthma action plan (PAAP)
Number of subjects: 60
Study 31210140 — intervention group
Group type: COMPARATOR
Intervention: Written asthma action plan (WAAP)
Number of subjects: 60
Study 27687851 — intervention group
Group type: EXPERIMENTAL
Intervention: Minerva Endometrial Ablation System
Number of subjects: 153
Study 27687851 — intervention group
Group type: COMPARATOR
Intervention: Rollerball ablation
Number of subjects: 153
Study 25721567 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mA anodal tDCS on right parietal cortex (P4)
Number of subjects: 24
Study 25721567 — intervention group
Group type: COMPARATOR
Intervention: 1.5 mA anodal tDCS on left dorsolateral (F3)
Number of subjects: 24
Study 25721567 — intervention group
Group type: COMPARATOR
Intervention: 1.5 mA anodal tDCS on left parietal (P3)
Number of subjects: 24
Study 25721567 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 24
Study 23266650 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine manipulator (RUMI) used in group A
Number of subjects: 110
Study 23266650 — intervention group
Group type: COMPARATOR
Intervention: No uterine manipulator used in group B
Number of subjects: 110
Study 21649457 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated green tea extract (GTE) 1,500 mg daily for 16 weeks
Number of subjects: 80
Study 21649457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 19234815 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine, 0.5 microg x kg(‐1)
Number of subjects: 15
Study 19234815 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam, 0.025 mg x kg(‐1)
Number of subjects: 15
Study 19234815 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 15
Study 16720593 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day
Number of subjects: 788
Study 16720593 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use (observational cohort)
Number of subjects: 788
Study 16720593 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use prior to first screening
Number of subjects: 788
Study 16720593 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use >3 years
Number of subjects: 788
Study 16720593 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use with >1 defined daily dose
Number of subjects: 788
Study 16720593 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use with >2 defined daily doses
Number of subjects: 788
Study 16720593 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin users
Number of subjects: 788
Study 16720593 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin non-users
Number of subjects: 788
Study 16720593 — intervention group
Group type: COMPARATOR
Intervention: Comparison of GFR between groups
Number of subjects: 788
Study 15448611 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg levobupivacaine with 25 microg fentanyl
Number of subjects: 40
Study 15448611 — intervention group
Group type: COMPARATOR
Intervention: Half the dose of levobupivacaine and fentanyl (1.25 mg levobupivacaine with 12.5 microg fentanyl)
Number of subjects: 40
Study 11268266 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil, 1200 mg/d (n = 1264)
Number of subjects: 2531
Study 11268266 — intervention group
Group type: COMPARATOR
Intervention: placebo (n = 1267)
Number of subjects: 2531
Study 9495299 — intervention group
Group type: EXPERIMENTAL
Intervention: FGF‐I (0.01 mg/kg body weight)
Number of subjects: 20
Study 11271180 — intervention group
Group type: EXPERIMENTAL
Intervention: Venovenous bypass
Number of subjects: 0
Study 11271180 — intervention group
Group type: COMPARATOR
Intervention: Control (no venovenous bypass)
Number of subjects: 0
Study 2567793 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide (oral administration, 800 mg three times daily for 7 days)
Number of subjects: 0
Study 2567793 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide (oral administration, 30 min before test meal)
Number of subjects: 0
Study 2567793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 5673963 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 5
Study 5673963 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulants
Number of subjects: 5
Study 107583 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous sodium fluoride treatment
Number of subjects: 0
Study 107583 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent sodium fluoride treatment
Number of subjects: 0
Study 107583 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31828528 — intervention group
Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 50
Study 31828528 — intervention group
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula (HFNC)
Number of subjects: 50
Study 30774322 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose physical activity (180 minutes/week)
Number of subjects: 110
Study 30774322 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-dose physical activity (120 minutes/week)
Number of subjects: 110
Study 30774322 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study 30431582 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaxilose test (GT)
Number of subjects: 147
Study 30431582 — intervention group
Group type: COMPARATOR
Intervention: Hydrogen breath test (HBT)
Number of subjects: 147
Study 26758747 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin for 3 days
Number of subjects: 2430
Study 26758747 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 days
Number of subjects: 2430
Study 26758747 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 2430
Study 26758747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2430
Study 24433249 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia (CBT‐I) consisting of sleep restriction, psychoeducation about sleep, stabilization of the circadian rhythm, and challenging and correcting sleep state misperception, in three to eight sessions.
Number of subjects: 0
Study 24433249 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) consisting of pharmacological and supportive psychosocial treatment.
Number of subjects: 0
Study 23057482 — intervention group
Group type: EXPERIMENTAL
Intervention: Yamamoto New Scalp Acupuncture (YNSA)
Number of subjects: 0
Study 23057482 — intervention group
Group type: COMPARATOR
Intervention: Standard poststroke motor rehabilitation (Control)
Number of subjects: 0
Study 18668363 — intervention group
Group type: EXPERIMENTAL
Intervention: E-T-CMF (epirubicin-alkylator based adjuvant chemotherapy with paclitaxel)
Number of subjects: 279
Study 18668363 — intervention group
Group type: COMPARATOR
Intervention: E-CMF (epirubicin-alkylator based adjuvant chemotherapy without paclitaxel)
Number of subjects: 279
Study 18668363 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant hormone therapy
Number of subjects: 279
Study 17166221 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 4483
Study 17166221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4483
Study 17166221 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors of magnesium sulphate group
Number of subjects: 4483
Study 17166221 — intervention group
Group type: COMPARATOR
Intervention: Survivors of placebo group
Number of subjects: 4483
Study 14989560 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte/macrophage colony stimulating factor (GM-CSF) at a dose of 10 microg/kg for 14 days
Number of subjects: 40
Study 14989560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 14989560 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte/macrophage colony stimulating factor (GM-CSF)
Number of subjects: 40
Study 10752807 — intervention group
Group type: EXPERIMENTAL
Intervention: BB-882 (4 mg loading dose on the first day, followed by 96 mg/24 hrs for up to 120 hrs)
Number of subjects: 152
Study 10752807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 10752807 — intervention group
Group type: EXPERIMENTAL
Intervention: BB-882
Number of subjects: 152
Study 8968293 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured educational intervention
Number of subjects: 52
Study 8968293 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional education methods)
Number of subjects: 52
Study 1403212 — intervention group
Group type: EXPERIMENTAL
Intervention: One reminder letter offering free influenza immunization without an appointment
Number of subjects: 3
Study 1403212 — intervention group
Group type: EXPERIMENTAL
Intervention: Two sequential reminder letters offering free influenza immunization without an appointment
Number of subjects: 3
Study 1403212 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3
Study 3890666 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.1% dexamethasone drops
Number of subjects: 56
Study 3890666 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroid group
Number of subjects: 56
Study 31396727 — intervention group
Group type: EXPERIMENTAL
Intervention: CTB-001
Number of subjects: 24
Study 28953447 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab maintenance therapy (375 mg/m² every 2 months for 3 years)
Number of subjects: 240
Study 28953447 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 240
Study 25515624 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) integrity scores for NRCPs
Number of subjects: 15
Study 25515624 — intervention group
Group type: COMPARATOR
Intervention: Motivational interviewing (MI) integrity scores for RCPs
Number of subjects: 15
Study 22922954 — intervention group
Group type: EXPERIMENTAL
Intervention: Print-based materials/pedometer group
Number of subjects: 287
Study 22922954 — intervention group
Group type: EXPERIMENTAL
Intervention: Print-based materials/pedometer plus telephone counseling group
Number of subjects: 287
Study 22922954 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 287
Study 21831969 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 87
Study 21831969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 21831969 — intervention group
Group type: COMPARATOR
Intervention: Rituximab and Placebo
Number of subjects: 87
Study 18794162 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (CC)
Number of subjects: 72
Study 18794162 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian diathermy (LOD)
Number of subjects: 72